Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

647
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
647

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: [177Lu]-PSMA-617-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE): An Open-label, Randomised, Phase 2 Study.

European urology·2026
Same author

Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.

Radiology. Imaging cancer·2026
Same author

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results.

European journal of nuclear medicine and molecular imaging·2026
Same author

Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Fibroblast activation protein inhibitor-PET/CT in lung cancer: a prospective single-center study with histopathological correlation of fibroblast activation protein expression.

International journal of clinical oncology·2026
Same author

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

Related Experiment Video

Updated: Feb 23, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.

Matthias Eiber1,2, Wolfgang P Fendler3,4, Steven P Rowe5

  • 1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California matthias.eiber@tum.de.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|September 3, 2017
PubMed
Summary

Prostate-specific membrane antigen (PSMA) ligands are revolutionizing prostate cancer (PC) management. PSMA-targeted PET imaging and radioligand therapy show high efficacy and safety for diagnosing and treating PC, even in recurrent or metastatic cases.

Keywords:
imagingprostate cancerprostate-specific membrane antigentherapy

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.2K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.7K

Related Experiment Videos

Last Updated: Feb 23, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

1.2K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.7K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Chemistry

Background:

  • Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells, making it a key therapeutic target.
  • Glu-urea-based PSMA ligands are central to current advancements in PC imaging and therapy.
  • Clinical translation of PSMA-targeting agents has significantly impacted PC management.

Purpose of the Study:

  • To provide a comprehensive review of low-molecular-weight PSMA ligands for PET imaging and radioligand therapy.
  • To highlight clinically adopted PSMA-targeting agents and their applications.
  • To summarize the current literature on PSMA ligand efficacy and safety in prostate cancer.

Main Methods:

  • Review of current literature on PSMA ligands for PET imaging and radioligand therapy.
  • Analysis of clinical data on 68Ga- and 18F-labeled PSMA agents for PET imaging.
  • Evaluation of 177Lu-PSMA radioligand therapy outcomes and safety profiles.

Main Results:

  • PSMA ligand PET imaging demonstrates high detection rates for biochemical recurrence, even with low PSA levels.
  • PSMA ligand PET imaging is superior to cross-sectional imaging for detecting metastatic lymph nodes in primary PC.
  • 177Lu-PSMA radioligand therapy shows comparable efficacy to other agents with a favorable safety profile for metastatic castration-resistant PC.

Conclusions:

  • PSMA-targeted PET imaging and radioguided surgery offer improved diagnostic and therapeutic capabilities for prostate cancer.
  • PSMA ligand PET imaging leads to significant changes in management for both primary and recurrent prostate cancer.
  • 177Lu-PSMA radioligand therapy presents a safe and effective option for advanced prostate cancer, expanding treatment possibilities.